| [1] |
Kisseleva T, Brenner D. 2021. Molecular and cellular mechanisms of liver fibrosis and its regression. |
| [2] |
Hammerich L, Tacke F. 2023. Hepatic inflammatory responses in liver fibrosis. |
| [3] |
Parola M, Pinzani M. 2019. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. |
| [4] |
Friedman SL, Pinzani M. 2022. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. |
| [5] |
Keam SJ. 2024. Resmetirom: first approval. |
| [6] |
Brisnovali NF, Haney C, Goedeke L. 2024. Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis. |
| [7] |
Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, et al. 2026. Semaglutide therapy for metabolic dysfunction – associated steatohepatitis: November 2025 updates to AASLD practice guidance. |
| [8] |
Noureddin M, Kowdley KV, Odrljin T, Bain G, Zhao J, et al. 2026. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. |
| [9] |
Ni T, Li XY, Lu N, An T, Liu ZP, et al. 2016. Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. |
| [10] |
Wu ZQ, Rowe RG, Lim KC, Lin Y, Willis A, et al. 2014. A Snail1/Notch1 signalling axis controls embryonic vascular development. |
| [11] |
Grande MT, Sánchez-Laorden B, López-Blau C, De Frutos CA, Boutet A, et al. 2015. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. |
| [12] |
Manetti M, Romano E, Rosa I, Guiducci S, Bellando-Randone S, et al. 2017. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. |
| [13] |
Jayachandran A, Königshoff M, Yu H, Rupniewska E, Hecker M, et al. 2009. SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis. |
| [14] |
Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, et al. 2011. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. |
| [15] |
Rowe RG, Lin Y, Shimizu-Hirota R, Hanada S, Neilson EG, et al. 2011. Hepatocyte-derived Snail1 propagates liver fibrosis progression. |
| [16] |
Wang P, Kang Q, Wu WS, Rui L. 2024. Hepatic Snai1 and Snai2 promote liver regeneration and suppress liver fibrosis in mice. |
| [17] |
Bao L, Chu Y, Kang H. 2023. SNAI1-activated long non-coding RNA LINC01711 promotes hepatic fibrosis cell proliferation and migration by regulating XYLT1. |
| [18] |
Tan S, Lu Y, Xu M, Huang X, Liu H, et al. 2019. β-Arrestin1 enhances liver fibrosis through autophagy‐mediated Snail signaling. |
| [19] |
Sugimoto A, Saito Y, Wang G, Sun Q, Yin C, et al. 2025. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. |
| [20] |
Trépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, et al. 2018. Combination of gene expression signature and model for end-stage liver disease score predicts survival of patients with severe alcoholic hepatitis. |
| [21] |
Jeong BK, Choi WI, Choi W, Moon J, Lee WH, et al. 2024. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. |
| [22] |
Steixner-Kumar AA, Santacruz D, Geiger T, Rust W, Böttner D, et al. 2025. Single-cell landscape of peripheral immune cells in MASLD/MASH. |
| [23] |
Uchinami H, Seki E, Brenner DA, D'Armiento J. 2006. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. |
| [24] |
Wang L, Mazagova M, Pan C, Yang S, Brandl K, et al. 2019. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. |
| [25] |
Li ZW, Ruan B, Yang PJ, Liu JJ, Song P, et al. 2023. Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells. |
| [26] |
Mederacke I, Dapito DH, Affò S, Uchinami H, Schwabe RF. 2015. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. |
| [27] |
Pan C, Liu J, Gao Y, Yang M, Hu H, et al. 2023. Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. |
| [28] |
Gao YS, Qian MY, Wei QQ, Duan XB, Wang SL, et al. 2020. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. |
| [29] |
Ren B, Li Y, Di L, Cheng R, Liu L, et al. 2024. A naturally derived small molecule compound suppresses tumor growth and metastasis in mice by relieving p53-dependent repression of CDK2/Rb signaling and the Snail-driven EMT. |
| [30] |
Ren BX, Zeng ZL, Deng L, Hu JM, Chen MZ, et al. 2025. Genetic and pharmacological targeting of Snail inhibits atherosclerosis by relieving intraplaque endothelium dysfunction and associated inflammation. |
| [31] |
Geng F, Zhong Y, Su H, Lefai E, Magaki S, et al. 2023. SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells. |
| [32] |
Tao J, Wu Z, Liang Y, Wang J, Tang M, et al. 2025. Lhx2 specifically expressed in HSCs promotes liver regeneration and inhibits liver fibrosis. |
| [33] |
Schwabe RF, Brenner DA. 2025. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease. |
| [34] |
Yang W, He H, Wang T, Su N, Zhang F, et al. 2021. Single-cell transcriptomic analysis reveals a hepatic stellate cell–activation roadmap and myofibroblast origin during liver fibrosis in mice. |
| [35] |
Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. 2000. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. |
| [36] |
Singh D, Deshmukh RK, Das A. 2021. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells. |
| [37] |
Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, et al. 2004. Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells. |
| [38] |
Sharvit E, Abramovitch S, Reif S, Bruck R. 2013. Amplified inhibition of stellate cell activation pathways by PPAR-γ, RAR and RXR agonists. |
| [39] |
Man S, Deng Y, Ma Y, Fu J, Bao H, et al. 2023. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5. |
| [40] |
Zhao M, Wang L, Wang M, Zhou S, Lu Y, et al. 2022. Targeting fibrosis: mechanisms and clinical trials. |
| [41] |
Parola M, Pinzani M. 2024. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies. |
| [42] |
Kumar V, Xin X, Ma J, Tan C, Osna N, et al. 2021. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. |
| [43] |
Bao Z, Zeng W, Zhang D, Wang L, Deng X, et al. 2022. SNAIL induces EMT and lung metastasis of tumours secreting CXCL2 to promote the invasion of M2-type immunosuppressed macrophages in colorectal cancer. |
| [44] |
Carmichael CL, Wang J, Nguyen T, Kolawole O, Benyoucef A, et al. 2020. The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. |
| [45] |
Elia I, Realini G, Di Mauro V, Borghi S, Bottoni L, et al. 2022. SNAI1 is upregulated during muscle regeneration and represses FGF21 and ATF3 expression by directly binding their promoters. |
| [46] |
Yang F, Li H, Li Y, Hao Y, Wang C, et al. 2021. Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis. |
| [47] |
Lan R, Lin J, Chen S, Lu Z, Gong Y, et al. 2025. Communication initiated by hepatocytes: the driver of HSC activation and liver fibrosis. |
| [48] |
Gupta G, Khadem F, Uzonna JE. 2019. Role of hepatic stellate cell (HSC)-derived cytokines in hepatic inflammation and immunity. |
| [49] |
Qian H, Deng X, Huang ZW, Wei J, Ding CH, et al. 2015. An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells. |
| [50] |
Tsuchida T, Friedman SL. 2017. Mechanisms of hepatic stellate cell activation. |
| [51] |
Felli E, Nulan Y, Ortega-Ribera M, Fernández-Iglesias A, Gracia-Sancho J. 2026. The role of liver sinusoidal endothelial cells in liver diseases: key players in health and pathology. |
| [52] |
Zhou Y, Zhao D, Ma Q, Xu J, Cai Y, et al. 2025. Endothelial adenosine receptor 2A loss alleviates diabetic vascular calcification by blocking CREB1-SNAI1-driven EndMT. |
| [53] |
Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, et al. 2015. Snail is a direct target of hypoxia-inducible factor 1α (HIF1α) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. |
| [54] |
Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, et al. 2008. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. |
| [55] |
Cai Y, Li H, Liu M, Pei Y, Zheng J, et al. 2018. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. |
| [56] |
Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, et al. 2022. A researcher’s guide to preclinical mouse NASH models. |